OTCMKTS:NWPHF - Newron Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.25 0.00 (0.00 %) (As of 04/22/2019)Previous Close$9.25Today's Range$9.25 - $9.2552-Week Range$7.98 - $9.25Volume25 shsAverage VolumeN/AMarket Capitalization$165.02 millionP/E RatioN/ADividend YieldN/ABeta0.44 ProfileChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of safinamide in Japan and Asian territories. The company was founded in 1998 and is headquartered in Bresso, Italy. Receive NWPHF News and Ratings via Email Sign-up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NWPHF Previous Symbol CUSIPN/A CIKN/A WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.17 million Price / Sales10.88 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees24 Outstanding Shares17,840,000Market Cap$165.02 million Next Earnings DateN/A OptionableNot Optionable Newron Pharmaceuticals (OTCMKTS:NWPHF) Frequently Asked Questions What is Newron Pharmaceuticals' stock symbol? Newron Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NWPHF." Has Newron Pharmaceuticals been receiving favorable news coverage? News articles about NWPHF stock have been trending negative on Sunday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Newron Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the immediate future. Who are some of Newron Pharmaceuticals' key competitors? Some companies that are related to Newron Pharmaceuticals include Kura Oncology (KURA), Stemline Therapeutics (STML), Advanz Pharma (CXRXF), TG Therapeutics (TGTX), Organogenesis (ORGO), Lexicon Pharmaceuticals (LXRX), Crinetics Pharmaceuticals (CRNX), Aurinia Pharmaceuticals (AUPH), Akebia Therapeutics (AKBA), Viking Therapeutics (VKTX), CannTrust (CTST), Odonate Therapeutics (ODT), Puma Biotechnology (PBYI), OvaScience (OVAS) and Obseva (OBSV). What other stocks do shareholders of Newron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Newron Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Celldex Therapeutics (CLDX), Canopy Growth (CGC), BioCryst Pharmaceuticals (BCRX), Axovant Sciences (AXON), Alnylam Pharmaceuticals (ALNY), Abeona Therapeutics (ABEO), PureTech Health (PRTC), Nordex (NDX1) and Dialog Semiconductor (DLG). Who are Newron Pharmaceuticals' key executives? Newron Pharmaceuticals' management team includes the folowing people: Mr. Stefan Weber, CEO & Exec. Director (Age 54)Mr. Roberto Galli, VP of Fin.Mr. Marco Caremi, Exec. VP of Bus. Devel. (Age 62)Dr. Ravi Anand, Chief Medical Officer (Age 62)Mr. Dennis Dionne, VP of Commercial Affairs (Age 69) How do I buy shares of Newron Pharmaceuticals? Shares of NWPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Newron Pharmaceuticals' stock price today? One share of NWPHF stock can currently be purchased for approximately $9.25. How big of a company is Newron Pharmaceuticals? Newron Pharmaceuticals has a market capitalization of $165.02 million and generates $15.17 million in revenue each year. Newron Pharmaceuticals employs 24 workers across the globe. MarketBeat Community Rating for Newron Pharmaceuticals (OTCMKTS NWPHF)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 63 (Vote Outperform)Underperform Votes: 80 (Vote Underperform)Total Votes: 143MarketBeat's community ratings are surveys of what our community members think about Newron Pharmaceuticals and other stocks. Vote "Outperform" if you believe NWPHF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWPHF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What causes a recession? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.